Journal profile · Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
Cell Reports Medicine
ISSN 2666-3791 · Elsevier · United States · Monthly · Founded 2020
Cell Reports Medicine: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 13.97; fully open access; APC about USD 5,790; median 228 days to acceptance (122 articles, last 24 months); community-reported acceptance: 32.34%; 455 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cell Reports Medicine is published by Elsevier and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction and CAR-T cell therapy research, together about 26% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Cell Reports Medicine is a premium open-access journal from Cell Press publishing cutting-edge research in translational and clinical biomedical sciences that inform and influence human health and medicine.The content published in Cell Reports Medicine reaches a broad range of scientists and clinicians across the spectrum of medical disciplines, ensuring that your work will be both visible and accessible. The journal publishes original research that ranges from exciting concepts in human biology, health, and disease to all phases of clinical work. We encourage submissions featuring innovative ideas that open up new directions in clinical research and practice, as well as studies that provide critical information that enriches our understanding of current standards of care in diagnosis, treatment, and prognosis. This includes, but is not limited to, translational studies, clinical trials in all areas of medicine including long-term trial follow-ups as well as work in genomics, biomarker discovery, and developments in technology that contribute to diagnostics, treatment, and healthcare. Studies based on vertebrate model organisms also fall within the scope of the journal, provided that the results are directly relevant to human health and disease.Like our sister journal Cell Reports, we will consider impactful, single-point papers called reports, in addition to longer articles. Large datasets, techniques, and tools for the community can also be considered under the article format. We will also publish reviews covering recent literature in emerging and active fields.The professional in-house scientific editors at Cell Reports Medicine work closely with authors, reviewers, and the journal's editorial board to ensure exemplary editorial process, fair and robust peer review, and rapid dissemination and communication of your research.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine9.6%
- Immune Cell Function and InteractionImmunology and Microbiology8.2%
- CAR-T cell therapy researchMedicine8.1%
- SARS-CoV-2 and COVID-19 ResearchMedicine7.5%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.1%
- COVID-19 Clinical Research StudiesMedicine5.1%
- Gut microbiota and healthBiochemistry, Genetics and Molecular Biology5.1%
- Immune cells in cancerImmunology and Microbiology4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
| Minor | Cell Biology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cell Biology | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
| Minor | Cell Biology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 13.97LetPub ·
- Impact factor (publisher)
- 14Publisher website ·
- CiteScore 2026-06
- 15.9LetPub ·
- CiteScore (publisher)
- 15.9Publisher website ·
- SJR 2026-06
- 4.93LetPub ·
- SNIP 2026-06
- 2.32LetPub ·
- h-index
- 105OpenAlex ·
- i10-index
- 1,252OpenAlex ·
- 2-year mean citedness
- 12.17OpenAlex ·
- Self-citation rate
- 0.7%LetPub ·
- Share of gold OA articles
- 99.73%LetPub ·
Volume
- Articles per year
- 417LetPub ·
Articles by year OpenAlex count · 2,267 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 408 | 408 | 486 |
| 2025 | 455 | 455 | 4,681 |
| 2024 | 429 | 429 | 10,556 |
| 2023 | 374 | 374 | 12,426 |
| 2022 | 292 | 292 | 10,528 |
| 2021 | 216 | 216 | 13,744 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
228 daysMedian, submission to acceptance · P25–P75 171 days – 308 days
- Acceptance to online
- median 27 days (117 articles)
- Submission to online
- median 257 days
- Sample
- 122 articles with submission and acceptance dates (981 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3.31 weeksLetPub ·
- Average acceptance (community reports)
- 32.34%LetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 43 daysPublisher website ·
- Submission to acceptance
- 205 daysPublisher website ·
- Acceptance to publication
- 27 daysPublisher website ·
- Submission to publication (journal-reported)
- about 36 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 5,790 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 5,620 / EUR 5,210 / GBP 4,500 / JPY 697,050 | — | — | |
| LetPub | USD 5,460 | Yes | — | |
| Publisher website | USD 5,790 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 5,790 (excluding taxes). This journal is taking part in the GPOA program.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United States
- Language
- English
- Frequency
- Monthly
- Founded
- 2020
- ISSN
- 2666-3791
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cell Reports Medicine
What CAS zone is Cell Reports Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cell Reports Medicine is in Zone 1 of Medicine, and in Zone 1 of the minor category Medicine, Research & Experimental / Cell Biology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cell Reports Medicine?
The latest impact factor listed by LetPub is 13.97; CiteScore 15.9, h-index 105.
How long does peer review take at Cell Reports Medicine?
Based on the dates recorded on 122 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 228 days (interquartile range 171–308 days); authors report an average review time of about 3.31 weeks; the community-reported acceptance is “32.34%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cell Reports Medicine?
According to LetPub and DOAJ records, Cell Reports Medicine is indexed in SCIE, Scopus and DOAJ.
Is Cell Reports Medicine open access, and what is the APC?
Cell Reports Medicine is a fully open-access journal. APC about USD 5,790.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .